CV Sciences, Inc.
CVSI evidence brief
What we can confirm
- BioSniper Score:
- 3.5 / 10
- Market Cap:
- $4.5M
- Lead Asset:
- cvsi-007 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for CVSI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CVSI
CV Sciences, Inc. (CVSI) is a biotech and consumer products company that develops and markets plant-based protein products and CBD-based wellness supplements, while also advancing a preclinical pipeline candidate for smokeless tobacco addiction.
Key risk: Early-stage pipeline
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$4.5M
Cash Runway
—
Lead Asset
cvsi-007 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for CV Sciences, Inc..
CV Sciences, Inc. (CVSI) is a biotech and consumer products company that develops and markets plant-based protein products and CBD-based wellness supplements, while also advancing a preclinical pipeline candidate for smokeless tobacco addiction.
- Total revenue of $3.0M and net income of -$0.8M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $1.6M and total debt of $0.0M as of 2026-06-30 [sec].
- Pipeline candidate cvsi-007 is in preclinical development for smokeless tobacco use and addiction, combining CBD and nicotine [pipeline].
- Acquired Cultured Foods Sp. z.o.o., a European manufacturer of plant-based protein products, in December 2023 [sec_mda · as of 2026-03-26].
- Launched Lunar Fox™ brand in January 2025 for U.S. distribution of plant-based products, and Ignite men's performance formula containing CBD in August 2025 [sec_mda · as of 2026-03-26] [news · published 2025-08-27].
What works
- Zero total debt as of 2026-06-30, indicating no outstanding borrowings [sec].
- Diversified product portfolio with plant-based protein brands (Cultured Foods™, Lunar Fox™) and CBD wellness supplements (Ignite), reducing reliance on a single revenue stream [sec_mda · as of 2026-03-26] [news · published 2025-08-27].
- Preclinical pipeline candidate cvsi-007 targets a specific addiction market (smokeless tobacco) with a novel CBD-nicotine combination [pipeline].
What to weigh
- Net loss of -$0.8M as of 2026-06-30, indicating the company is not yet profitable [sec].
- Shareholders' equity of $1.6M is relatively low, suggesting limited financial cushion [sec].
- Pipeline is at an early preclinical stage with no disclosed clinical trial data, implying years of development and regulatory risk before potential market entry [pipeline].
- The company's core CBD business faces competitive pressure from larger players like GW Pharmaceuticals (now Jazz Pharmaceuticals) and Harmony Biosciences [pipeline].
From the filings
Quoted directly from source documents.
CV Sciences acquired Cultured Foods Sp. z.o.o. in December 2023.
“On December 7, 2023, we entered into a Membership Interest Purchase Agreement, pursuant to which we purchased all of the outstanding equity interests in Cultured Foods Sp. z.o.o., resulting in Cultured Foods becoming a wholly owned subsidiary of the Company.”
SEC MD&A · March 26, 2026
CV Sciences launched the Ignite men's performance formula in August 2025.
“CV Sciences launched Ignite, a new men's performance formula containing CBD.”
News · August 27, 2025
Catalyst timeline
- 2024-08-13 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial and operational updates.
- 2024-11-14 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial and operational updates.
- 2025-03-27 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial and operational updates.
- 2025-05-14 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial and operational updates.
- 2025-08-13 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial and operational updates.
- 2025-11-13 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial and operational updates.
- 2026-03-26 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial and operational updates.
- 2026-05-14 · Earnings Report - SEC 8-K filing — Quarterly earnings report providing financial and operational updates.
Risks & what to watch (4)›
Key risks
- Early-stage pipeline — Pipeline candidate cvsi-007 is preclinical with no clinical data, facing high development risk and long timeline [pipeline].
- Ongoing net losses — Net loss of -$0.8M as of 2026-06-30 indicates lack of profitability, which may pressure cash reserves [sec].
- Low shareholders' equity — Shareholders' equity of $1.6M as of 2026-06-30 provides limited financial buffer against losses or downturns [sec].
- Competitive CBD market — CBD space includes established players like Jazz Pharmaceuticals and Harmony Biosciences, creating competitive pressure [pipeline].
What to watch
- Progress of preclinical candidate cvsi-007 toward IND filing and clinical trials [pipeline].
- Revenue growth and path to profitability from plant-based and CBD product lines [sec] [sec_mda · as of 2026-03-26].
- Any future SEC filings or earnings calls for updated financials and pipeline updates [catalyst].
- Market adoption of new brands Lunar Fox™ and Ignite in their respective categories [sec_mda · as of 2026-03-26] [news · published 2025-08-27].
Sources: Catalysts · Competitor trials · News · Pipeline · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run CV Sciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CV Sciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 3.15 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for CV Sciences, Inc.?
CV Sciences, Inc. (CVSI) is a biotech and consumer products company that develops and markets plant-based protein products and CBD-based wellness supplements, while also advancing a preclinical pipeline candidate for smokeless tobacco addiction.
What is CV Sciences, Inc.'s lead drug candidate?
CV Sciences, Inc.'s most advanced tracked candidate is cvsi-007 (Preclinical) for smokeless tobacco use and addiction.
Who is the CEO of CV Sciences, Inc.?
Mr. Joseph D. Dowling is the chief executive officer of CV Sciences, Inc. (CVSI).
Where is CV Sciences, Inc. headquartered?
CV Sciences, Inc. (CVSI) is headquartered in San Diego, CA, United States.
What therapeutic areas does CV Sciences, Inc. focus on?
CV Sciences, Inc. develops therapies across Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.